Periodic assessment of (ET-1) and Nitric Oxide(NO) in hypertensive disorders of pregnancy (HDP)
Hypertensive Disorders of Pregnancy (HDP) is an independent risk factors of cardiovascular (CVS) disease. The prevalence of Hypertensive Disorders of Pregnancy (HDP) in Malaysia is approximately 23.3 per 1000 live births Endothelin-1 (ET-1), a potent vasoconstriction, has been identified as a piv...
| Main Authors: | , , , |
|---|---|
| Format: | Conference or Workshop Item |
| Language: | English English |
| Published: |
2019
|
| Subjects: | |
| Online Access: | http://irep.iium.edu.my/71528/ http://irep.iium.edu.my/71528/ http://irep.iium.edu.my/71528/12/FAOPS%202019%20FINAL%20EDITED%20poster%20pdf.pdf http://irep.iium.edu.my/71528/23/71528_Periodic%20assessment%20of%20%28ET-1%29.pdf |
| Summary: | Hypertensive Disorders of Pregnancy (HDP) is an independent risk factors of cardiovascular (CVS) disease.
The prevalence of Hypertensive Disorders of Pregnancy (HDP) in Malaysia is approximately 23.3 per 1000 live births Endothelin-1 (ET-1), a potent vasoconstriction, has been identified as a pivotal mediator in HDP.
Disturbances in nitric oxide (NO) bioavailability found in endothelial dysfunction may increase susceptibility to cardiovascular disease such as hypertension.
HDP is defined as systolic blood pressure >= 140 mmHg and/or diastolic blood pressure >= 90 mmHg during pregnancy.
HDP : gestational hypertension (GH), chronic hypertension (CH), pre-eclampsia (PE), and GH/CH superimposed with PE. (GH is diagnosed at >= 20 weeks and resolves <= 12 weeks postpartum. PE: proteinuria component and CH includes women already previously diagnosed with essential hypertension prior to the pregnancy. |
|---|